Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07208370
Starting soon Not applicable

Outcomes of Gillian Barrie Syn

NCT07208370 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Not applicable
Started
2025-10-01
Last updated
2025-10-06

Condition(s) studied

Outcome of Gillian Barrie

Investigational drug(s) / intervention(s)

clinical assessment

clinical assessment: standraized clinical evaluation to assess disease sevirity and progration

Study summary

This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.

Eligibility

Sex
ALL
Min age
1 Month
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * All Pediatric patients (1 month to 18 years old) admitted with acute flaccid ascending paralysis and diagnosed as GBS. Consent obtained from parents or legal guardians for participation and follow-up. Exclusion Criteria: * Children with pre-existing neuromuscular disorders. Patients with incomplete medical records or those lost to follow-up. Cases diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).

Primary outcome measure(s)

  • Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months — first 3 months after diagnosis
    Proportion of pediatric patients with Guillain-Barré Syndrome achieving full recovery, as assessed by the Hughes Functional Grading Scale, within 3 months of diagnosis.

Trial sites (1)

FacilityCityRegionStatus
Assuit University Hospital Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07208370 on ClinicalTrials.gov ↗ ← All trials in Egypt